Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Dossier - 02/05/2011 Corals (the photo shows an endoscopic image) appear to convert light for use by the algae.

    Molecular bionics – inspirations from the microworld for the macroworld

    Knowledge about the molecular organisation of structural and functional biological properties has led to the establishment of a new field of research molecular bionics. Everything that can be learnt from the macromolecular observation of interesting natural phenomena is complemented in this field by observations on the smallest i.e. molecular level. Processes and materials that have been optimised in the course of evolution are thus able to…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/molecular-bionics-inspirations-from-the-microworld-for-the-macroworld
  • Article - 12/01/2011 13302_de.jpg

    How milk, cheese, yoghurt and curd cheese can be kept free from “genetic engineering”

    Bacteriophages introduce their DNA into bacteria where they quickly reproduce and eventually destroy the host organism. Phages are omnipresent in nature and some can be dangerous for humans. They also represent a huge contamination risk in the production of fermented food. Canadian researchers Lvesque et al. 2005 estimate that phages cause around 10 per cent of all production losses in the diary industry where they infest bacteria such as…

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-milk-cheese-yoghurt-and-curd-cheese-can-be-kept-free-from-genetic-engineering
  • Article - 10/01/2011 13256_de.jpg

    Review: What does the cell factory of the future look like?

    A symposium on “Cell Factories of the Future” was held at the Laupheim-based company Rentschler Biotechnologie on 14th and 15th October 2010. The event attracted around 70 scientists from academia and industry and will now take place every two years. The symposium focused on new biomanufacturing developments and technologies, and included lectures on (animal) cells, cell factories and the future of recombinant protein production.

    https://www.gesundheitsindustrie-bw.de/en/article/news/review-what-does-the-cell-factory-of-the-future-look-like
  • Article - 20/12/2010 13278_de.jpg

    Gicon: Using controllable biogas production to create virtual power stations

    Conventional biogas plants have the disadvantage that the production of energy cannot be controlled in a flexible way. Therefore, Großmann Ingenieur Consult GmbH (GICON) has developed a fast, simple method for controlling biogas production from renewable resources. In addition, the two-stage dry-wet fermentation process with split hydrolysis makes it possible to control the two stages independently. Heribert Krämer, head of the GICON subsidiary…

    https://www.gesundheitsindustrie-bw.de/en/article/news/gicon-using-controllable-biogas-production-to-create-virtual-power-stations
  • Press release - 15/11/2010 12969_de.png

    ASPEX- an advanced Schizosaccharomyces expression system

    The ASPEX system Asahi Glass Schizosaccharomyces Expression is a full-scale contract manufacturing service for recombinant proteins with up to the 3000 L scale. It is based on S. pombe an endotoxin-free fission yeast isolated from east African beer. Examples for gene expressions in the ASPEX system are manifold. The dedicated production facility located close to the Research Center is organized under cGMP rules and thus enables supply of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/aspex-an-advanced-schizosaccharomyces-expression-system
  • Article - 14/10/2010 Dimitrios Vasilakopoulos from Nestlé

    Understanding what happens in dough

    In cooperation with the Nestl Research Centre Dr. Helmut Trautmann with his company abiotec AG has developed a gas volume monitor for the analysis of dough samples. The monitor makes an important contribution to the development as well as to the quality assurance of food. In addition to being used in the food technology sector the highly sensitive measurement device can also be used in the pharmaceutical and environmental sectors for example in…

    https://www.gesundheitsindustrie-bw.de/en/article/news/understanding-what-happens-in-dough
  • Press release - 09/09/2010

    Jiangnan University, Wuxi

    Jiangnan University JU is one of Chinas key universities of the 211 Project and functions under the Ministry of Education. The university host the National Engineering Laboratory of Fermentation Technology the Key Laboratory of Industrial Biotechnology the Engineering Research Center of Bioactive Product Processing Jiangsu Province and the Collection of Industrial Microbes Resources.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/jiangnan-university-wuxi
  • Article - 21/11/2009 The photo shows a man with glasses and wearing a lab coat. The man has folded his arms and is laughing. There are three glass containes to his left, containing red liquids.<br />

    “Big companies do not specialise enough”

    Dr. Aziz Cayli worked for many years for big biotechnology and pharmaceutical companies. In 2005 he took the path of independence and set up the company CELLCA based in Laupheim Germany. Here Cayli talks to Christoph Bächtle about the fact that having the right partners plays a decisive role in establishing a company.

    https://www.gesundheitsindustrie-bw.de/en/article/news/big-companies-do-not-specialise-enough
  • Press release - 13/11/2009 The photo shows a fermentation room with four bioreactors.

    Second-generation biofuels

    The Distillery for Research and Training at the University of Hohenheim has been reopened after the completion of renovation work costing around 1.2 million euros. The distillery is now equipped with a computer-operated process-control system and modern sensors, all state-of-the-art technology for the fermentation processes at Hohenheim. The new distillery pilot plant has a fermentation room for work with genetically modified organisms.…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/second-generation-biofuels
  • Article - 23/10/2009 09901_de.jpg

    Agrano – organic yeast for the industry

    Riegel-based Agrano GmbH & Co. has been producing Bioreal Organic Yeast since 1996. The company is a subsidiary of Hanover-based Martin Braun KG, which is a member of the Oetker Group. The company’s product is used by bakers in the production of organically flawless bread as well as makers of 100% organic soups and spreads.

    https://www.gesundheitsindustrie-bw.de/en/article/news/agrano-organic-yeast-for-the-industry
  • Article - 24/09/2009 The photo shows several plastics products: tent pegs, a lid of a feeding coup, a small red bottle lid, a knife, a cosmetics container, two razers, a cup, a lipstick casing and a powder container.

    Bacteria to produce bioplastics

    Polyhydroxyalkanoates are storage substances produced and stored by many cells plants and bacteria only in times when they lack lack important nutrients. A particular property of these plastics-related biopolymers is that their composition and hence their material properties can be regulated by the fermentation process.

    https://www.gesundheitsindustrie-bw.de/en/article/news/bacteria-to-produce-bioplastics
  • Article - 14/09/2009 09640_de.jpg

    SensScreen Technologies: Magnetic separation to conquer biotechnological areas of application

    In terms of protein purification, the biopharmaceutical industry is increasingly reaching its technical and economic limits. The currently used chromatography procedures are expensive, time-consuming and associated with high product losses due to the large number of individual processing steps involved. Special magnetic microparticles, such as those developed by the chemist Dr. Jochen F. Peter with his recently established company SensScreen…

    https://www.gesundheitsindustrie-bw.de/en/article/news/sensscreen-technologies-magnetic-separation-to-conquer-biotechnological-areas-of-application
  • Article - 30/07/2009 09257_de.jpg

    Dragnet investigation for substance killers

    The Ulm-based company Labor Dr. Merk Kollegen with over 40 employees is a specialist company identifying foreign bodies such as viruses bacteria and toxins in biopharmaceuticals and medical products. In addition the medium-sized company has been developing producing and marketing diagnostics for medical use for almost 40 years.

    https://www.gesundheitsindustrie-bw.de/en/article/news/dragnet-investigation-for-substance-killers
  • Dossier - 30/07/2009 Downstream GMP production suite (Photo: Rentschler Biotechnologie)

    Downstream processing: bottleneck purification process

    The fermentation processes that are used by biopharmaceutical manufacturers have shown to lead to increasing quantities of therapeutic proteins. However this increase in turn leads to capacity bottlenecks in the subsequent purification process known as downstream processing and is associated with high costs. Downstream processing comprises up to 80 per cent of the entire production costs. Producers are increasingly recognising the present need…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/downstream-processing-bottleneck-purification-process
  • Article - 29/07/2009 09254_de.jpg

    Protein crystallisation: an attractive alternative to protein purification

    The production of pure crystals is a method that is normally used for the determination of the spatial structure of a protein using X-ray defraction. Crystalline proteins have a very regular structure, meaning that contaminations can to a large extent be excluded. Therefore, protein crystals only contain a small number of foreign substances, which makes them a lot more stable in solution than proteins are. Due to the aforementioned properties,…

    https://www.gesundheitsindustrie-bw.de/en/article/news/protein-crystallisation-an-attractive-alternative-to-protein-purification
  • Dossier - 16/07/2009 09218_de.jpg

    Patents – the exploitations of inventions in the life sciences

    According to statistics from the European Patent Office a total of 1065 biotechnological patents were filed in 2007 by inventors based in Germany. This puts Germany second behind the USA. In the coming years experts expect that a much larger number of biotech patents will be filed. For life sciences inventors the registration of patents quite often represents a real challenge. People entering the world of patents and licences are faced with a…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/patents-the-exploitations-of-inventions-in-the-life-sciences
  • Article - 30/03/2009

    More than milk and business

    Although there is very little difference between the biotechnological methods used in the dairy industry and those used in other industries nevertheless biotechnology operates differently here. Why can certain goals sometimes be reached more effectively without academic research?

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-than-milk-and-business
  • Article - 09/02/2009 Picture of Dr. Bodo Philipp

    Bodo Philipp – the discovery of the general principles of bacterial interaction

    Dr. Bodo Philipp from the University of Constance specifically focuses on ecologically relevant activities of bacteria for example cell-cell interactions. His findings could prove effective in removing bacteria from areas where high levels of hygiene are required thereby making it possible to prevent life-threatening bacterial infectious diseases. Dr. Bodo Philipp uses the much feared Pseudomonas aeruginosa bacteria as model organisms for his…

    https://www.gesundheitsindustrie-bw.de/en/article/news/bodo-philipp-the-discovery-of-the-general-principles-of-bacterial-interaction
  • Press release - 18/08/2008

    One third of all biopharmaceuticals get a "sugar coating"

    More than 50 of recombinant proteins are altered while they are being synthesized in the cells sometimes once and sometimes several times. Experts call these alterations post-translational modifications.

    https://www.gesundheitsindustrie-bw.de/en/article/news/one-third-of-all-biopharmaceuticals-get-a-sugar-coating
  • Article - 02/06/2008 At first, there was a lot of demand for small production batches; the picture shows a 250-l fermenter (Photo: Rentschler Biotechnologie)

    New production alliance in South West Germany

    Rentschler Biotechnologie and Boehringer Ingelheim have signed a preferred partnership agreement. Clients will benefit from the combined development and manufacturing know-how. Compatible bioprocessing methods guarantee a seamless project transfer between the companies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-production-alliance-in-south-west-germany
  • Dossier - 24/04/2008 title=

    Contract manufacture: the order books remain full

    The market for therapeutic proteins is continuing to grow in double figures. Current estimates of the total market value are in the range of 60 to 70 billion US dollars and the market is estimated to grow by 13 per cent p.a. up until 2010. Biopharmaceutical contract manufacturers have established themselves on the market and market observers estimate that the number of biopharmaceutical medicines will grow from 100 2005 to approx. 150 until 2010.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/contract-manufacture-the-order-books-remain-full

Page 2 / 2

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search